Edwards Lifesciences (EW)

Edwards Lifesciences beats Q3 earnings, raises full-year guidance on strong structural heart portfolio growth and robust TAVR & TMTT sales.

Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly calls.

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th

Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday.

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Wednesday to uncover the stocks that are gapping in the S&P500 index.

Edwards Lifesciences (NYSE: EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.53%. Currently, Edwards Lifesciences has a market capitalization of $45.32 billion.

One was recently acquired by a much bigger company.

These three firms in the fast-changing healthcare sector stand out to analysts for their strong product lineups, defensible technology, and notable pipelines.

Millennium Management's Q2 2025 13F reveals big bets on crypto (IBIT, PLTR) & healthcare (EW, INSM), with tech rebalancing. Read key changes!

A longtime leader in financial services tops the list.

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.

The FTC complaint alleges that if Edwards acquires JenaValve, it would gain control over the two most advanced TAVR-AR devices.

Edwards Lifesciences may avoid bearishness but is likely to trade sluggishly through 2027, as key cycle phases signal limited upside potential.